In the United States
alone, an estimated 26 million people have Type 2 diabetes while another 80
million or so people are pre-diabetic. Recognizing that there are urgent,
unfulfilled medical needs for both the pre-diabetic and diabetic community,
Boston Therapeutics is concentrating on creating better technology to prevent
diabetes and its complications.
Considering the
varied and dangerous complications that stem from uncontrolled diabetes (such
as heart disease, stroke, and kidney damage), Boston Therapeutics’ goal is to
better control glucose levels in patients throughout the day using innovations
in complex carbohydrate chemistry.
The key diabetic
solution in the company’s arsenal is PAZ320, a non-systemic, non-toxic chewable
drug candidate that is intended to be taken before meals to reduce the
post-meal elevation of blood glucose in patients living with Type 2 diabetes.
PAZ320 slows down the enzymes that release glucose from complex carbohydrates
in foods during digestion and thereby reduces the amount of glucose absorbed
through the intestine.
Boston Therapeutics
is developing the PAZ320 drug for potential use with metformin, a popular
anti-diabetic drug, and as a better alternative to Acarbose, which has side
effects and limited functionality. PAZ320 has already completed a Phase 2
clinical trial to reduce post-meal glucose elevation and the company hopes to
take it to Phase 3 trial by the third quarter of 2014.
Alongside PAZ320,
Boston Therapeutics has two other products in the pipeline: IPOXYN and OXYFEX.
IPOXYN, a universal
oxygen carrier and cell bodyguard, is an injectable drug candidate for the
prevention of necrosis, the death of cells in an organ or tissue due to a
failure of blood supply. IPOXYN would also be appropriate for the treatment of
hypoxia, a deficiency in the amount of oxygen reaching the tissues, as well as
other ischemic conditions which may lead to necrosis. IPOXYN oxygen carriers
are in the pre-clinical stage of drug development.
OXYFEX, a
reproduction of IPOXYN, is Boston Therapeutics’ offering to the veterinary
market. OXYFEX is able to serve as an oxygen delivery mechanism for animals
suffering from damaged or ischemic tissue due to traumatic and surgical blood
loss.
Boston Therapeutics
has engaged in designing, producing, and marketing novel compounds and
therapeutic drugs that address diabetes and other inflammatory diseases since
its start in 2009.
For more
information, visit www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment